FDA stops trials of Amgen's Sensipar after teen's death

02/27/2013 | Reuters

The FDA halted all clinical trials of Amgen's Sensipar involving children following the death of a 14-year old. The agency said it is not sure whether Sensipar, which is approved for the reduction of blood calcium levels in adults, had a role in the death. "Amgen is working as rapidly as possible to understand the circumstances of what happened. This analysis is ongoing and will be concluded as quickly as possible," the firm said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY